HY 1272
Alternative Names: HY-1272Latest Information Update: 05 Mar 2024
At a glance
- Originator Newsoara Biopharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Jan 2024 Preclinical trials in Solid tumours in China (IV), prior to January 2024
- 23 Jan 2024 Newsoara Biopharma plans a phase I trial for Solid tumors (Late-stage disease, Metastatic disease, Monotherapy) and Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) (IV) in December 2024 (NCT06218940)